Department of Hematology and Coagulation, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Vaccine. 2021 Feb 12;39(7):1035-1038. doi: 10.1016/j.vaccine.2020.12.073. Epub 2021 Jan 20.
Our aim was to assess response and side effects of 4 doses of TBE vaccine to patients (pts) after allo- and autologous stem cell transplantation (SCT).
Included were 104 pts with leukaemia, myeloma and lymphoma, median age 61 yrs.
Vaccine (FSME-Immun®) was given at 9, 10, 12, and 21 months post-transplant. Serum samples were obtained before and after vaccinations. Healthy controls (n = 27) received 3 vaccinations. Assessments of TBE specific IgG antibodies were performed by Enzygnost anti-TBE ELISA test (Siemens, Sweden).
Antibody levels (>12 U/mL; "seropositivity") were seen in 77% and 80% of pts after allo- and autoSCT; IgG levels; 89 vs 94 U/mL. Ongoing chronic GvHD and immunosuppression (n = 29) was associated with sero-negativity in the last sample (p = 0.007). All controls (n = 27) developed protective antibody levels.
TBE vaccination was safe, and 4 doses starting 9 months post-SCT, induced seropositivity in a vast majority of pts.
我们的目的是评估 4 剂 TBE 疫苗对异基因和自体干细胞移植（SCT）后患者（pts）的反应和副作用。
包括白血病、骨髓瘤和淋巴瘤患者 104 例，中位年龄 61 岁。
疫苗（FSME-Immun®）在移植后 9、10、12 和 21 个月时给予。在接种前后采集血清样本。健康对照组（n=27）接受 3 次疫苗接种。使用 Enzygnost anti-TBE ELISA 试验（Siemens，瑞典）检测 TBE 特异性 IgG 抗体。
异基因和自体 SCT 后，77%和 80%的患者出现抗体水平（>12 U/mL；“血清阳性”）；IgG 水平分别为 89 和 94 U/mL。持续的慢性 GvHD 和免疫抑制（n=29）与最后一次样本的血清阴性相关（p=0.007）。所有对照组（n=27）均产生保护性抗体水平。
TBE 疫苗接种安全，4 剂疫苗在 SCT 后 9 个月开始接种，可使绝大多数患者产生血清阳性。
